Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt

Summary

Sofosbuvir has been recently recommended as a possible antiviral for COVID-19, based on structural studies and multiple alignment analysis. By comparing the positive-stranded RNA genomes of HCV and SARS-CoV-2, it has been postulated that sofosbuvir might be an optimal nucleotide analogue to repurpose for COVID-19 treatment

Timeline

Start

2020-11-01

Primary completion

2020-11-30

Completion

2020-12-12

Drugs

Indications